Blood centres: The effect of cytokine therapy on transfusion medicine

Transfusion Science

Volumn 18, Issue 1, 1997, Pages 147-157

  Pamphilon, Derwood H ^a  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKINE;

HEMATOLOGIC DISEASE; HUMAN; LEUKEMIA; LYMPHOMA; MEGAKARYOCYTE; MYELOMA; PERIPHERAL BLOOD STEM CELL; PHOTODYNAMIC THERAPY; REVIEW; STEM CELL TRANSPLANTATION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VIRUS TRANSMISSION;

EID: 0347937659     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(96)00091-4     Document Type: Article

References (27)

1. Goodnough LT, Anderson KC, Kurtz S, et al.: (committee report), Indications and guidelines for the use of haemopoietic growth factors. Transfusion 1993; 33:944-959.
2. Wurnig C, Windhager R, Schwameis E, et al.: Prevention of chemotherapy-induced anaemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996; 36:155-159.
3. Price TH, Goodnough LT, Vogler WR, et al: The effect of recombinant human erythropoietin on the efficacy of autologous blood donation in patients with low hematocrits: a multicenter, randomized, double-blind, controlled trial. Transfusion 1996; 36:29-36.
4. Tandy NP, Taylor MA: Platelet concentrates for transfusion: control of production and storage. Med Lab Sci 1980; 37:127-136.
5. Fijnheer R, Pietersz RNI, De Korte D: Platelet activation during preparation of platelet concentrates; a comparison of the platelet-rich plasma and the buffy coat methods. Transfusion 1990; 30:634-638.
6. Burgstaler EA, Pineda AA, Brecher MA: Plateletpheresis: comparison of platelet yields, processing time, and white cell content with two apheresis systems. Transfusion 1993; 33:393-398.
7. Burgstaler EA, Pineda AA: Evaluation of the Haemonetics MCS apheresis system for platelet yields and white blood cell content. Transfusion 1993; 33 (1):3S.
8. Klein HG: It seemed a pity to throw away the red cells: selective component collection (editorial). Transfusion 1993; 33:788-790.
9. Inwards D, Kessinger A: Peripheral blood stem cell transplantation: Historical perspective, current status, and prospects for the future. Trans Med Rev 1992; VI (3):183-190.
10. Gianni AM, Siena S, Bregni M, et al.: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2:580-585.
11. Pettengell R, Morgenstern GR, Woll PJ et al.: Peripheral blood progenitor cell transplantation in lymphoma and leukaemia using a single apheresis. Blood 1993; 82:3770-3777.
12. Schmitz N, Linch DC, Dreger P et al.: Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347:353-357.
13. Maher DW, Lieschke GJ, Green M et al.: Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 1994; 121:492-501.
14. Broudy VC, Lin NL, Kaushansky K: Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995; 85:1719-1726.
15. Farese AM, Hunt P, Boone T, MacVittie TJ: Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995; 86:54-59.
16. Kaushansky K: Thrombopoietin: the primary regulator of platelet production. Blood 1995; 86:419-431.
17. Doughty HA, Murphy MF, Metcalfe P, Rohatiner AZS, Lister TA, Waters AH: Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994; 66:200-205.
18. Slichter SJ, Harker LA: Thrombocytopenia: mechanisms and management of defects in platelet production. Clin Haematol 1978; 7:523-539.
19. Ciavarella D, Reed RL, Counts RB et al.: Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Brit Journal Haem 1987; 67:365-368.
20. Vahdat L, Antman K: High-dose therapy for breast cancer. Blood Reviews 1995; 9:191-200.
21. Triozzi PL: Autologous bone marrow and peripheral blood progenitor transplant for breast cancer. Lancet 1994; 344:418-419.
22. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with haematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J. Clin One 1995; 13:2483-2489.
23. Wallace EL, Churchill WH, Surgenor DM, et al.: Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995; 35:802-812.
24. Vyas GN: Inactivation and removal of blood-borne viruses. Transfusion 1995; 35:367-370.
25. Dodd RY, Moroff G, Wagner S, et al.: Inactivation of viruses in platelet suspensions that retain their in vitro characteristics: comparison of psoralenultraviolet A and merocyanine 540-visible light methods. Transfusion 1991; 31:483-490.
26. Lin L, Londe H, Janda JM, Hanson CV, Corash L: Photochemical inactivation of pathogenic bacteria in human platelet concentrates. Blood 1994; 9:2698-2706.
27. Novotny VMJ, van Doom R, Witvliet MD, Claas FHJ, Brand A: Occurrence of allogeneic HLA and non-HLA antibodies after transfusion of prestorage filtered platelets and red blood cells: A prospective study. Blood 1995; 85:1736-1741.